The ADRB2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell pool targeting ADRB2 in the HeLa cell line. This heterogeneous population harbors diverse gene disruptions at the beta-2 adrenergic receptor locus, creating a loss-of-function model without clonal isolation. Designed for cost-effective and flexible applications, the polyclonal format is ideal for functional genomics and pooled pharmacological studies where uniform knockout is not required. The product allows interrogation of ADRB2-dependent processes in a well-characterized human cervical adenocarcinoma background.
HeLa cells are an immortalized human cervical adenocarcinoma line originally derived from Henrietta Lacks, containing HPV18 sequences that drive their transformed phenotype. Widely used for their robust growth and transfectability, HeLa cells provide a reliable platform for cancer biology, signal transduction, and GPCR research. Their epithelial origin and endogenous receptor expression make them a relevant context for studying ADRB2-mediated signaling and its contributions to cancer-relevant phenotypes such as proliferation and migration.
ADRB2 encodes the beta-2 adrenergic receptor, a Gs-coupled GPCR activated by catecholamines like epinephrine. Agonist binding stimulates adenylate cyclase via Gs alpha, elevating cAMP and activating PKA, which phosphorylates CREB to regulate gene transcription. Concurrently, receptor phosphorylation by GRK2 and GRK5 recruits beta-arrestin-1/2, which scaffold MAPK/ERK signaling and promote receptor internalization and desensitization. In certain contexts, ADRB2 switches coupling to Gi, activating PI3K/AKT pathways. Interacting proteins including caveolin-1 and NHERF1 modulate receptor trafficking. These pathways position ADRB2 as a central regulator of bronchodilation, metabolic control, and cellular growth responses.
In the HeLa context, ADRB2 knockout ablates a key catecholamine-sensing node, enabling dissection of ??2-adrenergic contributions to cancer cell signaling. This model can reveal compensatory mechanisms among adrenergic receptors and clarify the role of ADRB2 in processes such as cell cycle progression and apoptosis resistance. The polyclonal nature ensures diverse disruption alleles, reducing clonal bias and enhancing the representation of knockout phenotypes in pooled assays.
This polyclonal knockout population is suited for cAMP accumulation assays, BRET-based beta-arrestin recruitment studies, and western blot analysis of phospho-CREB and phospho-ERK. Migration and viability assays (transwell, MTT) can assess ADRB2??s influence on HeLa motility and survival under beta-agonist or antagonist treatment. Immunofluorescence or flow cytometry can examine receptor surface expression and internalization. For custom inquiries or additional information, please reach out to Ascent Research.
